Informatie:
Fout:
ID
34179
Beschrijving
Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.; ODM derived from: https://clinicaltrials.gov/show/NCT02334709
Link
https://clinicaltrials.gov/show/NCT02334709
Trefwoorden
Versies (1)
- 15-01-19 15-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
15 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Carcinoma, Renal Cell NCT02334709
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
signed informed consent
boolean
ID.2
Item
diagnosis of rcc with clear-cell component histology
boolean
ID.3
Item
at least 3 extracranial measurable metastatic lesions per recist
boolean
ID.4
Item
karnofsky performance score >60
boolean
ID.5
Item
patients should have undergone cytoreductive treatment of their rcc at least 6 weeks prior to inclusion
boolean
ID.6
Item
patients should have adequate organ function for tki treatment.
boolean
ID.7
Item
prior systemic treatment for rcc
boolean
ID.8
Item
uncontrolled central nervous metastases
boolean
ID.9
Item
prior radiotherapy interfering with sbrt
boolean
ID.10
Item
any disorder precluding understanding of trial information.
boolean